Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - tekući ekstrakt lista trputca i cvijeta crnog sljeza natrijev askorbat - sirup - 2,5 g + 65 mg/5 ml - urbroj: 5 ml sirupa (1 odmjerna žličica) sadrži: - 2,5 g tekućeg ekstrakta iz plantago lanceolata l. s.l., folium (list trpuca) i malva sylvestris l., flos (cvijet crnog sljeza) što odgovara 0,25 g lista trpuca i 0,25 g cvijeta crnog sljeza; ekstrakcijsko otapalo: voda - 65 mg askorbatne kiseline u obliku natrijevog askorbata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

imunološki zavod d.d., rockefellerova 2, zagreb - cjepivo protiv tuberkuloze (bcg) cryodesiccatum - prašak i otapalo za suspenziju za injekciju - 0,75 mg (2-8 x 106 cfu) - urbroj: 1 ml rekonstituiranog cjepiva sadržava: 0,75 mg (2-8 x 106 cfu) živih, atenuiranih bakterija mycobacterium bovis (bcg), danski soj 1331

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

kedrion s.p.a., ai conti, castelvecchio pascoli, barga (lucca), italija - albumin, ljudski - otopina za infuziju - 200 g/l - urbroj: 1 l otopine za infuziju sadrži ukupno 200 g proteina plazme od kojih je najmanje 95% albumina, ljudskog

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medika d.d. capraška 1 10000 zagreb -

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomide - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1)orpatients s brzo razvija težak relapsing ublažavanje multiplom sklerozom određuje se 2 ili više teških recidiva u roku od jedne godine, s 1 ili više gadolinij revitalizacije lezija na mr mozga ili značajno povećanje opterećenja t2 lezija u odnosu na najnoviji mri.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan ireland limited - финголимод hidroklorid - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 i 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Europska Unija - hrvatski - EMA (European Medicines Agency)

correvio - vernakalant hidroklorid - fibrilacija atrija - srčana terapija - brza transformacija nedavnog početka фибрилляции vrlo značajan u синусовый ritam i za odrasle:za non-kirurških bolesnika: fibrilacija atrija .

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - cjepiva - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 i 5. 1 in product information document). korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multipla skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).